CAMP4 Therapeutics (NASDAQ:CAMP) Shares Cross Above Fifty Day Moving Average – Here’s Why

CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report)’s share price crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $3.85 and traded as high as $4.08. CAMP4 Therapeutics shares last traded at $3.86, with a volume of 108,509 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on CAMP shares. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Tuesday, September 29th. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Chardan Capital lowered their target price on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Needham & Company LLC initiated coverage on CAMP4 Therapeutics in a report on Thursday, October 15th. They issued a “buy” rating and a $8.00 target price for the company. Finally, UBS Group set a $15.00 price target on CAMP4 Therapeutics in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, CAMP4 Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.44.

Get Our Latest Analysis on CAMP

CAMP4 Therapeutics Trading Up 2.5%

The business’s 50-day moving average is $3.84 and its two-hundred day moving average is $4.20.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last released its earnings results on Thursday, November 5th. The Wireless communications provider reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.17). The business had revenue of $1.90 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,276.33% and a negative return on equity of 182.39%. On average, research analysts predict that CAMP4 Therapeutics Corporation will post -0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Andrew J. Schwab sold 400,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the transaction, the director directly owned 2,033,270 shares of the company’s stock, valued at approximately $8,214,410.80. The trade was a 16.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kelly Gold purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average cost of $3.96 per share, for a total transaction of $39,600.00. Following the completion of the acquisition, the chief financial officer directly owned 10,000 shares in the company, valued at $39,600. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 546,728 shares of company stock valued at $2,280,864 in the last 90 days. Corporate insiders own 21.69% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CAMP. Integral Health Asset Management LLC bought a new position in shares of CAMP4 Therapeutics during the 3rd quarter valued at approximately $2,000,000. Empowered Funds LLC bought a new stake in shares of CAMP4 Therapeutics in the third quarter valued at $220,000. Landscape Capital Management L.L.C. purchased a new position in shares of CAMP4 Therapeutics during the 3rd quarter valued at $264,000. Bank of America Corp DE bought a new position in shares of CAMP4 Therapeutics during the 2nd quarter worth $78,000. Finally, Trails Edge Capital Partners LP purchased a new stake in CAMP4 Therapeutics in the 2nd quarter worth about $8,446,935.

CAMP4 Therapeutics Company Profile

(Get Free Report)

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.

Recommended Stories

Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.